36-Month Results from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran) Presented at NKF Spring Clinical Meetings

36-Month Results from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran) Presented at NKF Spring Clinical Meetings

During the National Kidney Foundation (NKF) 2023 Spring Clinical Meetings, we presented new 36-month results from the ILLUMINATE-A Phase 3 study of lumasiran in patients with primary hyperoxaluria type 1 (PH1).

Saland, et al. “Efficacy and Safety of Lumasiran in Patients with Primary Hyperoxaluria Type 1: 36-Month Analysis of the ILLUMINATE-A Trial”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.